| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2025 | Resolved | N/A |
| Chlorine | Monitoring | N/A | N/A | Jul 31, 2025 | Resolved | Eye and nose irritation; stomach discomfort |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 26, 2025 | Active | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2025 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2025 | Active | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2025 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2025 | Active | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2025 | Active | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2025 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2025 | Active | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2025 | Active | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2025 | Active | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2025 | Active | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2025 | Active | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 30, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 30, 2025 | Resolved | N/A |
| Groundwater Rule | Health-Based | N/A | N/A | Apr 12, 2025 | Resolved | N/A |
| Groundwater Rule | Health-Based | N/A | N/A | Apr 12, 2025 | Resolved | N/A |
| Groundwater Rule | Health-Based | N/A | N/A | Apr 12, 2025 | Resolved | N/A |
| Groundwater Rule | Health-Based | N/A | N/A | Apr 12, 2025 | Resolved | N/A |
| TTHM | Monitoring | N/A | N/A | Mar 31, 2025 | Active | N/A |
| TTHM | Monitoring | N/A | N/A | Mar 31, 2025 | Active | N/A |
| Chlorine | Monitoring | N/A | N/A | Mar 31, 2025 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Mar 31, 2025 | Resolved | Eye and nose irritation; stomach discomfort |
| Arsenic | Health-Based | N/A | 0.03 | Mar 31, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.03 | Mar 31, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.03 | Mar 31, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.03 | Mar 31, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.03 | Mar 31, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 28, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 28, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 28, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 28, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 28, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 28, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 28, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 28, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 28, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 28, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 28, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 28, 2025 | Resolved | N/A |
| Chlorine | Monitoring | N/A | N/A | Feb 28, 2025 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Feb 28, 2025 | Resolved | Eye and nose irritation; stomach discomfort |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 28, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 28, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 19, 2025 | Active | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2024 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Monitoring | N/A | N/A | Dec 31, 2024 | Active | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2024 | Resolved | N/A |
| TTHM | Monitoring | N/A | N/A | Dec 31, 2024 | Active | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2024 | Resolved | N/A |
| TTHM | Monitoring | N/A | N/A | Dec 31, 2024 | Active | N/A |
| TTHM | Monitoring | N/A | N/A | Dec 31, 2024 | Active | N/A |
| Total Haloacetic Acids (HAA5) | Monitoring | N/A | N/A | Dec 31, 2024 | Active | N/A |
| Total Haloacetic Acids (HAA5) | Monitoring | N/A | N/A | Dec 31, 2024 | Active | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2024 | Active | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2024 | Active | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2024 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 18 | Dec 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 18 | Dec 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 18 | Dec 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 18 | Dec 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 18 | Dec 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Dec 21, 2024 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Dec 19, 2024 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Dec 19, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Dec 19, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Dec 19, 2024 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Dec 19, 2024 | Active | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Surface Water Treatment Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Surface Water Treatment Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Interim Enhanced Surface Water Treatment Rule | Monitoring | N/A | N/A | Oct 31, 2024 | Resolved | N/A |
| Interim Enhanced Surface Water Treatment Rule | Monitoring | N/A | N/A | Oct 31, 2024 | Resolved | N/A |
| Interim Enhanced Surface Water Treatment Rule | Monitoring | N/A | N/A | Oct 31, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Oct 18, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Oct 18, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Active | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Active | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Active | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Active | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Active | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Active | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Active | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Active | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Active | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Active | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Active | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Active | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Active | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Active | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Active | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Active | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Active | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Active | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Active | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Oct 9, 2024 | Active | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Oct 1, 2024 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Oct 1, 2024 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Oct 1, 2024 | Active | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Interim Enhanced Surface Water Treatment Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Surface Water Treatment Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Interim Enhanced Surface Water Treatment Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Surface Water Treatment Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.013 | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.013 | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.013 | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.02 | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 23, 2024 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 4, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 4, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Arsenic | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.013 | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.013 | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.013 | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Active | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Active | N/A |
| Arsenic | Health-Based | N/A | 0.02 | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Public Notice | Monitoring | N/A | N/A | Jun 20, 2024 | Active | N/A |
| Interim Enhanced Surface Water Treatment Rule | Monitoring | N/A | N/A | May 31, 2024 | Resolved | N/A |
| Interim Enhanced Surface Water Treatment Rule | Monitoring | N/A | N/A | May 31, 2024 | Resolved | N/A |
| Interim Enhanced Surface Water Treatment Rule | Monitoring | N/A | N/A | May 31, 2024 | Resolved | N/A |
| Interim Enhanced Surface Water Treatment Rule | Monitoring | N/A | N/A | May 31, 2024 | Resolved | N/A |
| Groundwater Rule | Health-Based | N/A | N/A | May 11, 2024 | Resolved | N/A |
| Groundwater Rule | Health-Based | N/A | N/A | May 11, 2024 | Resolved | N/A |
| Groundwater Rule | Health-Based | N/A | N/A | May 11, 2024 | Resolved | N/A |
| Groundwater Rule | Health-Based | N/A | N/A | May 11, 2024 | Resolved | N/A |
| Groundwater Rule | Health-Based | N/A | N/A | May 11, 2024 | Resolved | N/A |
| Groundwater Rule | Health-Based | N/A | N/A | May 11, 2024 | Resolved | N/A |
| Groundwater Rule | Health-Based | N/A | N/A | May 11, 2024 | Resolved | N/A |
| Groundwater Rule | Health-Based | N/A | N/A | May 11, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 20, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 20, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 19, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 19, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 4, 2024 | Active | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2024 | Resolved | N/A |
| Arsenic | Monitoring | N/A | N/A | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.014 | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.014 | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.014 | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 29, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 29, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jan 25, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jan 25, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jan 19, 2024 | Active | N/A |
| TTHM | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| TTHM | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.012 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.012 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.012 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.012 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2023 | Active | N/A |
| Arsenic | Health-Based | N/A | 0.015 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.015 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2023 | Active | N/A |
| Arsenic | Health-Based | N/A | 0.015 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Oct 21, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Oct 21, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Oct 21, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Oct 21, 2023 | Resolved | N/A |
| E. COLI | Monitoring | 0 | N/A | Oct 3, 2023 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Oct 3, 2023 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Oct 3, 2023 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Oct 3, 2023 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Oct 1, 2023 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Oct 1, 2023 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Oct 1, 2023 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Oct 1, 2023 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Oct 1, 2023 | Active | N/A |
| Arsenic | Health-Based | N/A | 0.02 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Public Notice | Monitoring | N/A | N/A | Sep 23, 2023 | Active | N/A |
| Groundwater Rule | Health-Based | N/A | N/A | Aug 12, 2023 | Resolved | N/A |
| Groundwater Rule | Health-Based | N/A | N/A | Aug 12, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Jul 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Jul 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Jul 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Jul 31, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 22, 2023 | Active | N/A |
| Groundwater Rule | Health-Based | N/A | N/A | Jul 13, 2023 | Resolved | N/A |
| Groundwater Rule | Health-Based | N/A | N/A | Jul 13, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Chlorine | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | Eye and nose irritation; stomach discomfort |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Active | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Active | N/A |
| Arsenic | Health-Based | N/A | 0.011 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.011 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.011 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| E. COLI | Monitoring | 0 | N/A | Jun 2, 2023 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Jun 2, 2023 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2023 | Resolved | N/A |
| Interim Enhanced Surface Water Treatment Rule | Monitoring | N/A | N/A | May 31, 2023 | Resolved | N/A |
| Interim Enhanced Surface Water Treatment Rule | Monitoring | N/A | N/A | May 31, 2023 | Resolved | N/A |
| Surface Water Treatment Rule | Monitoring | N/A | N/A | May 31, 2023 | Resolved | N/A |
| Surface Water Treatment Rule | Monitoring | N/A | N/A | May 31, 2023 | Resolved | N/A |
| Chlorine | Monitoring | N/A | N/A | Mar 31, 2023 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Mar 31, 2023 | Resolved | Eye and nose irritation; stomach discomfort |
| Interim Enhanced Surface Water Treatment Rule | Monitoring | N/A | N/A | Mar 31, 2023 | Resolved | N/A |
| Interim Enhanced Surface Water Treatment Rule | Monitoring | N/A | N/A | Mar 31, 2023 | Resolved | N/A |
| Chlorine | Monitoring | N/A | N/A | Mar 31, 2023 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Mar 31, 2023 | Resolved | Eye and nose irritation; stomach discomfort |
| Arsenic | Health-Based | N/A | 0.02 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Public Notice | Monitoring | N/A | N/A | Mar 2, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Mar 2, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jan 1, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jan 1, 2023 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| TTHM | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| TTHM | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| TTHM | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| TTHM | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| TTHM | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| TTHM | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| TTHM | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| TTHM | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Interim Enhanced Surface Water Treatment Rule | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Interim Enhanced Surface Water Treatment Rule | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Surface Water Treatment Rule | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Surface Water Treatment Rule | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2022 | Active | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2022 | Active | N/A |
| Arsenic | Health-Based | N/A | 0.02 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Public Notice | Monitoring | N/A | N/A | Dec 4, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Dec 4, 2022 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Oct 8, 2022 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Oct 8, 2022 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Oct 8, 2022 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Oct 8, 2022 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Oct 1, 2022 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Oct 1, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2022 | Resolved | N/A |
| Chlorine | Monitoring | N/A | N/A | Sep 30, 2022 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Sep 30, 2022 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Sep 30, 2022 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Sep 30, 2022 | Resolved | Eye and nose irritation; stomach discomfort |
| Combined Uranium | Health-Based | N/A | 31 | Sep 30, 2022 | Resolved | N/A |
| Combined Uranium | Health-Based | N/A | 31 | Sep 30, 2022 | Resolved | N/A |
| Combined Uranium | Health-Based | N/A | 31 | Sep 30, 2022 | Resolved | N/A |
| Combined Uranium | Health-Based | N/A | 31 | Sep 30, 2022 | Resolved | N/A |
| Combined Uranium | Health-Based | N/A | 31 | Sep 30, 2022 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.019 | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.019 | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.019 | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.019 | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.019 | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Public Notice | Monitoring | N/A | N/A | Sep 28, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Sep 28, 2022 | Resolved | N/A |
| E. COLI | Monitoring | 0 | N/A | Sep 27, 2022 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Sep 27, 2022 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Aug 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Aug 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Aug 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Aug 31, 2022 | Resolved | N/A |
| E. COLI | Monitoring | 0 | N/A | Aug 1, 2022 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Aug 1, 2022 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| CARBON, TOTAL | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| CARBON, TOTAL | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Lead and Copper Rule | Health-Based | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Lead and Copper Rule | Health-Based | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Lead and Copper Rule | Health-Based | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Lead and Copper Rule | Health-Based | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Chlorine | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | Eye and nose irritation; stomach discomfort |
| Combined Uranium | Health-Based | N/A | 0.038 | Jun 30, 2022 | Resolved | N/A |
| Combined Uranium | Health-Based | N/A | 0.038 | Jun 30, 2022 | Resolved | N/A |
| Combined Uranium | Health-Based | N/A | 0.038 | Jun 30, 2022 | Resolved | N/A |
| Combined Uranium | Health-Based | N/A | 0.038 | Jun 30, 2022 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Active | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Active | N/A |
| Arsenic | Health-Based | N/A | 0.02 | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| E. COLI | Monitoring | 0 | N/A | Jun 29, 2022 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Jun 29, 2022 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| Groundwater Rule | Health-Based | N/A | N/A | Apr 18, 2022 | Active | N/A |
| Groundwater Rule | Health-Based | N/A | N/A | Apr 18, 2022 | Active | N/A |
| Groundwater Rule | Health-Based | N/A | N/A | Apr 18, 2022 | Active | N/A |
| Groundwater Rule | Health-Based | N/A | N/A | Apr 18, 2022 | Active | N/A |
| Groundwater Rule | Health-Based | N/A | N/A | Apr 18, 2022 | Active | N/A |
| Groundwater Rule | Health-Based | N/A | N/A | Apr 18, 2022 | Active | N/A |
| Groundwater Rule | Health-Based | N/A | N/A | Apr 18, 2022 | Active | N/A |
| Groundwater Rule | Health-Based | N/A | N/A | Apr 18, 2022 | Active | N/A |
| Groundwater Rule | Health-Based | N/A | N/A | Apr 18, 2022 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 1, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 1, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2022 | Resolved | N/A |
| Combined Uranium | Health-Based | N/A | 35 | Mar 31, 2022 | Resolved | N/A |
| Combined Uranium | Health-Based | N/A | 35 | Mar 31, 2022 | Resolved | N/A |
| Combined Uranium | Health-Based | N/A | 35 | Mar 31, 2022 | Resolved | N/A |
| Combined Uranium | Health-Based | N/A | 35 | Mar 31, 2022 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.02 | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Groundwater Rule | Health-Based | N/A | N/A | Mar 28, 2022 | Active | N/A |
| Groundwater Rule | Health-Based | N/A | N/A | Mar 28, 2022 | Active | N/A |
| Groundwater Rule | Health-Based | N/A | N/A | Mar 28, 2022 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Mar 1, 2022 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Mar 1, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Mar 1, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 28, 2022 | Resolved | N/A |
| Surface Water Treatment Rule | Monitoring | N/A | N/A | Feb 28, 2022 | Resolved | N/A |
| Surface Water Treatment Rule | Monitoring | N/A | N/A | Feb 28, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 28, 2022 | Resolved | N/A |
| Interim Enhanced Surface Water Treatment Rule | Monitoring | N/A | N/A | Feb 28, 2022 | Resolved | N/A |
| Interim Enhanced Surface Water Treatment Rule | Monitoring | N/A | N/A | Feb 28, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 19, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 19, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 12, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 12, 2022 | Resolved | N/A |
| Dalapon | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Dalapon | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Dalapon | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.011 | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Chlorine | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Eye and nose irritation; stomach discomfort |
| Arsenic | Health-Based | N/A | 0.011 | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.011 | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.011 | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.011 | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Chlorine | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Eye and nose irritation; stomach discomfort |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2021 | Active | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2021 | Active | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2021 | Active | N/A |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Arsenic | Health-Based | N/A | 0.02 | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Surface Water Treatment Rule | Monitoring | N/A | N/A | Nov 30, 2021 | Resolved | N/A |
| Surface Water Treatment Rule | Monitoring | N/A | N/A | Nov 30, 2021 | Resolved | N/A |
| Surface Water Treatment Rule | Monitoring | N/A | N/A | Nov 30, 2021 | Resolved | N/A |
| Surface Water Treatment Rule | Monitoring | N/A | N/A | Nov 30, 2021 | Resolved | N/A |
| Interim Enhanced Surface Water Treatment Rule | Monitoring | N/A | N/A | Nov 30, 2021 | Resolved | N/A |
| Interim Enhanced Surface Water Treatment Rule | Monitoring | N/A | N/A | Nov 30, 2021 | Resolved | N/A |
| Interim Enhanced Surface Water Treatment Rule | Monitoring | N/A | N/A | Nov 30, 2021 | Resolved | N/A |
| Interim Enhanced Surface Water Treatment Rule | Monitoring | N/A | N/A | Nov 30, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Nov 20, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Nov 20, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Nov 15, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Nov 15, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Oct 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Oct 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Oct 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Oct 31, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Oct 16, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Oct 16, 2021 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Oct 1, 2021 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Oct 1, 2021 | Resolved | N/A |
| TTHM | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| TTHM | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| TTHM | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| TTHM | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.011 | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.011 | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.011 | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.011 | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.011 | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.02 | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Public Notice | Monitoring | N/A | N/A | Sep 4, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Sep 4, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2021 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Active | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Active | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.019 | Jun 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.019 | Jun 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.019 | Jun 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.019 | Jun 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Jun 6, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Jun 6, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | May 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | May 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | May 31, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | May 31, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | May 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 30, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 28, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 28, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 27, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 27, 2021 | Resolved | N/A |
| Groundwater Rule | Health-Based | N/A | N/A | Apr 8, 2021 | Resolved | N/A |
| Groundwater Rule | Health-Based | N/A | N/A | Apr 8, 2021 | Resolved | N/A |
| Groundwater Rule | Health-Based | N/A | N/A | Apr 8, 2021 | Resolved | N/A |
| Groundwater Rule | Health-Based | N/A | N/A | Apr 8, 2021 | Resolved | N/A |
| Chlorine | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | Eye and nose irritation; stomach discomfort |
| Arsenic | Health-Based | N/A | 0.018 | Mar 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.018 | Mar 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.018 | Mar 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.018 | Mar 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Groundwater Rule | Health-Based | N/A | N/A | Mar 24, 2021 | Resolved | N/A |
| Groundwater Rule | Health-Based | N/A | N/A | Mar 24, 2021 | Resolved | N/A |
| Groundwater Rule | Health-Based | N/A | N/A | Mar 24, 2021 | Resolved | N/A |
| Groundwater Rule | Health-Based | N/A | N/A | Mar 24, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 28, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 28, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 24, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 24, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 24, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 24, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 18, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 18, 2021 | Resolved | N/A |